The International Diabetes Federation estimates that more than 285 million people world-wide have diabetes and 438 million people will have this disease within 20 years. Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of all diabetes and is characterized by insulin resistance combined with relatively reduced insulin secretion. The seven major markets for diabetes are expected to grow to 35 billion in 10 years driven by patient population expansion and novel therapies.

Come and join other diabetes experts at GTCbio’s 4th Diabetes Drug Discovery and Development Conference and hear key thought-leader`s opinions to these questions and many more. This important meeting will be held on March 7-8, 2011 in Philadelphia, PA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current and clinical drug development.

Sessions include:
Session I: New Therapeutic Targets for Diabetes
Session II: Diabetes and the Metabolic Syndrome Drug Development
Session III: Panel Discussion - Investment, Partnership and M&A Deals in Diabetes
Session IV: Clinical Drug Development in Diabetes
Session V: New Therapeutic Targets for Diabetes Cont`d
Session VI: Regulatory Landscape and the Impact on Drug Development and Discovery

Best regards,

2011 Conference Advisory Committee